"Nevirapine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
| Descriptor ID |
D019829
|
| MeSH Number(s) |
D03.383.725.506
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nevirapine".
Below are MeSH descriptors whose meaning is more specific than "Nevirapine".
This graph shows the total number of publications written about "Nevirapine" by people in this website by year, and whether "Nevirapine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 0 | 3 |
| 2006 | 5 | 0 | 5 |
| 2007 | 4 | 2 | 6 |
| 2008 | 1 | 2 | 3 |
| 2009 | 4 | 2 | 6 |
| 2010 | 5 | 0 | 5 |
| 2011 | 4 | 2 | 6 |
| 2012 | 3 | 1 | 4 |
| 2013 | 3 | 3 | 6 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nevirapine" by people in Profiles.
-
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. Antimicrob Agents Chemother. 2022 09 20; 66(9):e0238521.
-
Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component. J Acquir Immune Defic Syndr. 2021 10 01; 88(2):206-213.
-
Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial. PLoS One. 2021; 16(8):e0255250.
-
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. J Antimicrob Chemother. 2021 02 11; 76(3):718-721.
-
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenet Genomics. 2021 01; 31(1):17-27.
-
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis. AIDS. 2019 12 01; 33(15):2403-2413.
-
HIV diagnostic challenges in breast-fed infants of mothers on antiretroviral therapy. AIDS. 2019 09 01; 33(11):1751-1756.
-
Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa. J Int AIDS Soc. 2019 06; 22(6):e25284.
-
Reply to Van de Wijer et al. Clin Infect Dis. 2018 03 19; 66(7):1151-1152.
-
Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial. Clin Infect Dis. 2017 Aug 01; 65(3):477-485.